WO2014036897A1 - 咪唑啉类衍生物、其制备方法及其在医药上的应用 - Google Patents
咪唑啉类衍生物、其制备方法及其在医药上的应用 Download PDFInfo
- Publication number
- WO2014036897A1 WO2014036897A1 PCT/CN2013/082273 CN2013082273W WO2014036897A1 WO 2014036897 A1 WO2014036897 A1 WO 2014036897A1 CN 2013082273 W CN2013082273 W CN 2013082273W WO 2014036897 A1 WO2014036897 A1 WO 2014036897A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- dimethyl
- mmol
- general formula
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 150000002462 imidazolines Chemical class 0.000 title abstract description 4
- 229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 title abstract 2
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 36
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 229940123407 Androgen receptor antagonist Drugs 0.000 claims abstract description 7
- 239000003936 androgen receptor antagonist Substances 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 148
- -1 cyano, amino Chemical group 0.000 claims description 136
- 125000000217 alkyl group Chemical group 0.000 claims description 98
- 239000000203 mixture Substances 0.000 claims description 81
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 71
- 125000000623 heterocyclic group Chemical group 0.000 claims description 70
- 125000003118 aryl group Chemical group 0.000 claims description 54
- 229910052736 halogen Inorganic materials 0.000 claims description 52
- 150000002367 halogens Chemical group 0.000 claims description 52
- 125000001072 heteroaryl group Chemical group 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 48
- 125000001424 substituent group Chemical group 0.000 claims description 33
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 30
- 108010080146 androgen receptors Proteins 0.000 claims description 29
- 102000001307 androgen receptors Human genes 0.000 claims description 29
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 21
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 20
- 125000001188 haloalkyl group Chemical group 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 claims description 18
- 125000003342 alkenyl group Chemical group 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 230000001404 mediated effect Effects 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 239000003098 androgen Substances 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 229940088597 hormone Drugs 0.000 claims description 10
- 239000005556 hormone Substances 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 150000007942 carboxylates Chemical group 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 6
- 201000004384 Alopecia Diseases 0.000 claims description 6
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 6
- 206010006895 Cachexia Diseases 0.000 claims description 6
- 206010057672 Male sexual dysfunction Diseases 0.000 claims description 6
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 6
- 206010000496 acne Diseases 0.000 claims description 6
- 231100000360 alopecia Toxicity 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 206010020112 Hirsutism Diseases 0.000 claims description 5
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims description 5
- 238000006482 condensation reaction Methods 0.000 claims description 5
- 125000005604 azodicarboxylate group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 230000003042 antagnostic effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 239000000849 selective androgen receptor modulator Substances 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 279
- 235000019439 ethyl acetate Nutrition 0.000 description 122
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 117
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 96
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 87
- 238000006243 chemical reaction Methods 0.000 description 78
- 239000007787 solid Substances 0.000 description 74
- 238000004949 mass spectrometry Methods 0.000 description 72
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 60
- 238000005160 1H NMR spectroscopy Methods 0.000 description 53
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 239000000243 solution Substances 0.000 description 47
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 39
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 39
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 37
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 30
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 29
- 239000000047 product Substances 0.000 description 29
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 239000002904 solvent Substances 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 229910000027 potassium carbonate Inorganic materials 0.000 description 20
- 235000011181 potassium carbonates Nutrition 0.000 description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 18
- 229910000024 caesium carbonate Inorganic materials 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000001816 cooling Methods 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 13
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 13
- 235000011118 potassium hydroxide Nutrition 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 12
- 150000007529 inorganic bases Chemical class 0.000 description 12
- 125000003367 polycyclic group Chemical group 0.000 description 12
- 125000006413 ring segment Chemical group 0.000 description 12
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 11
- 235000011121 sodium hydroxide Nutrition 0.000 description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- 125000002619 bicyclic group Chemical group 0.000 description 10
- 239000012046 mixed solvent Substances 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 125000004414 alkyl thio group Chemical group 0.000 description 8
- 125000000000 cycloalkoxy group Chemical group 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- 125000003282 alkyl amino group Chemical group 0.000 description 7
- 125000005366 cycloalkylthio group Chemical group 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 7
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 101150041968 CDC13 gene Proteins 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 150000007530 organic bases Chemical class 0.000 description 6
- 239000011736 potassium bicarbonate Substances 0.000 description 6
- 235000015497 potassium bicarbonate Nutrition 0.000 description 6
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 6
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 6
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 235000017550 sodium carbonate Nutrition 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 229960003604 testosterone Drugs 0.000 description 6
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 6
- AIUTZIYTEUMXGG-UHFFFAOYSA-N 3,6-dioxabicyclo[3.1.0]hexane Chemical compound C1OCC2OC12 AIUTZIYTEUMXGG-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 230000001270 agonistic effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- SOZGHDCEWOLLHV-UHFFFAOYSA-N 2-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=CC=C1C#N SOZGHDCEWOLLHV-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- 101150029129 AR gene Proteins 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- ALEVEZMLPKTOBM-UHFFFAOYSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)cc(F)c1O Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)cc(F)c1O ALEVEZMLPKTOBM-UHFFFAOYSA-N 0.000 description 4
- 230000004544 DNA amplification Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- OVPHARXTEGNOCQ-UHFFFAOYSA-N [S].ClC(Cl)=O Chemical compound [S].ClC(Cl)=O OVPHARXTEGNOCQ-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 238000012925 biological evaluation Methods 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- HFMAZNJKNNRONT-UHFFFAOYSA-N tert-butyl n-[1-(hydroxymethyl)cyclopropyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1(CO)CC1 HFMAZNJKNNRONT-UHFFFAOYSA-N 0.000 description 4
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 4
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 3
- TYXKOMAQTWRDCR-UHFFFAOYSA-N 4-isothiocyanato-2-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC(N=C=S)=CC=C1C#N TYXKOMAQTWRDCR-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 150000001335 aliphatic alkanes Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008098 formaldehyde solution Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- USVVENVKYJZFMW-ONEGZZNKSA-N (e)-carboxyiminocarbamic acid Chemical class OC(=O)\N=N\C(O)=O USVVENVKYJZFMW-ONEGZZNKSA-N 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- QMCQBAJOOAMKBX-UHFFFAOYSA-N 1-(hydroxymethyl)cyclopropane-1-carbonitrile Chemical compound OCC1(C#N)CC1 QMCQBAJOOAMKBX-UHFFFAOYSA-N 0.000 description 2
- VYDQUABHDFWIIX-UHFFFAOYSA-N 2,2-difluoro-2-fluorosulfonylacetic acid Chemical compound OC(=O)C(F)(F)S(F)(=O)=O VYDQUABHDFWIIX-UHFFFAOYSA-N 0.000 description 2
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical compound CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- XDPCNPCKDGQBAN-UHFFFAOYSA-N 3-hydroxytetrahydrofuran Chemical compound OC1CCOC1 XDPCNPCKDGQBAN-UHFFFAOYSA-N 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- PMDYLCUKSLBUHO-UHFFFAOYSA-N 4-amino-2-(trifluoromethyl)benzonitrile Chemical compound NC1=CC=C(C#N)C(C(F)(F)F)=C1 PMDYLCUKSLBUHO-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- LKDNNAMFFCTLNR-UHFFFAOYSA-N CC(C)(C(N(C1=S)c(cc2)cc(C(F)(F)F)c2C#N)=O)N1c(cc1)cc(F)c1OCC1(CC1)C#N Chemical compound CC(C)(C(N(C1=S)c(cc2)cc(C(F)(F)F)c2C#N)=O)N1c(cc1)cc(F)c1OCC1(CC1)C#N LKDNNAMFFCTLNR-UHFFFAOYSA-N 0.000 description 2
- UANNZUNBDVDNBG-UHFFFAOYSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)cc(F)c1OC1CNC1 Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)cc(F)c1OC1CNC1 UANNZUNBDVDNBG-UHFFFAOYSA-N 0.000 description 2
- VIMSHSUYAZHWKM-UHFFFAOYSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)ccc1O Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)ccc1O VIMSHSUYAZHWKM-UHFFFAOYSA-N 0.000 description 2
- KRBMOYIWQCZVHA-MRXNPFEDSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)ccc1OC[C@@H](CO)O Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)ccc1OC[C@@H](CO)O KRBMOYIWQCZVHA-MRXNPFEDSA-N 0.000 description 2
- VWVQVICMKHENPI-UHFFFAOYSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1F)ccc1OC(CO)CO Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1F)ccc1OC(CO)CO VWVQVICMKHENPI-UHFFFAOYSA-N 0.000 description 2
- RGJULKMOAFMQJR-UHFFFAOYSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1F)ccc1OC1CNCC1 Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1F)ccc1OC1CNCC1 RGJULKMOAFMQJR-UHFFFAOYSA-N 0.000 description 2
- BIEHICPVPOPELF-UHFFFAOYSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1F)ccc1Oc1ccccc1C(NC)=O Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1F)ccc1Oc1ccccc1C(NC)=O BIEHICPVPOPELF-UHFFFAOYSA-N 0.000 description 2
- NWMDMRWOXWXQEY-UHFFFAOYSA-N CC(C)[N]C(C)C Chemical compound CC(C)[N]C(C)C NWMDMRWOXWXQEY-UHFFFAOYSA-N 0.000 description 2
- UTTKXDDXFUCUSC-UHFFFAOYSA-N CC1(OCC(CO1)CC1=CC=C(C=C1)S(=O)(=O)O)C Chemical compound CC1(OCC(CO1)CC1=CC=C(C=C1)S(=O)(=O)O)C UTTKXDDXFUCUSC-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- NFJGVKXEAUZSDV-UHFFFAOYSA-N NN.C(C)(=O)N(C)C Chemical compound NN.C(C)(=O)N(C)C NFJGVKXEAUZSDV-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- WWCNXHYRAKUQDB-SNVBAGLBSA-N [(3r)-oxolan-3-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@H]1COCC1 WWCNXHYRAKUQDB-SNVBAGLBSA-N 0.000 description 2
- WRWYGOVGIGCDLE-UHFFFAOYSA-N [O]c1ccccc1F Chemical group [O]c1ccccc1F WRWYGOVGIGCDLE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-M cyclopropanecarboxylate Chemical compound [O-]C(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-M 0.000 description 2
- 229960004671 enzalutamide Drugs 0.000 description 2
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- QSIIYQGIMJQZNE-UHFFFAOYSA-N methyl 1-[tert-butyl(dimethyl)silyl]oxycyclopropane-1-carboxylate Chemical compound CC(C)(C)[Si](C)(C)OC1(C(=O)OC)CC1 QSIIYQGIMJQZNE-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- PCPUMGYALMOCHF-UHFFFAOYSA-N oxolan-3-ylmethanol Chemical compound OCC1CCOC1 PCPUMGYALMOCHF-UHFFFAOYSA-N 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- QUERMGFVJPRMJL-UHFFFAOYSA-N tert-butyl azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC1 QUERMGFVJPRMJL-UHFFFAOYSA-N 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- GDJWDLUJZROSRN-UHFFFAOYSA-N thian-4-yl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1CCSCC1 GDJWDLUJZROSRN-UHFFFAOYSA-N 0.000 description 2
- 125000004149 thio group Chemical group *S* 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- AJKNNUJQFALRIK-UHFFFAOYSA-N 1,2,3-trifluorobenzene Chemical compound FC1=CC=CC(F)=C1F AJKNNUJQFALRIK-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- HIZZGKZEHBXFAQ-UHFFFAOYSA-N 1-[ethoxy(fluoromethyl)phosphoryl]oxyethane Chemical compound CCOP(=O)(CF)OCC HIZZGKZEHBXFAQ-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- NCTCZGRRDXIGIY-UHFFFAOYSA-N 1-methylcyclopropan-1-ol Chemical compound CC1(O)CC1 NCTCZGRRDXIGIY-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- YJYAGNPMQVHYAH-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxyethanol Chemical compound CC(C)(C)[Si](C)(C)OCCO YJYAGNPMQVHYAH-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- CAOBPKIQMNOCBO-UHFFFAOYSA-N 2-chloro-4-isothiocyanatobenzonitrile Chemical compound ClC1=CC(N=C=S)=CC=C1C#N CAOBPKIQMNOCBO-UHFFFAOYSA-N 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 1
- SVQCNROYIFLAMR-UHFFFAOYSA-N 2-methylbenzene-1,3-dicarbonitrile Chemical compound CC1=C(C#N)C=CC=C1C#N SVQCNROYIFLAMR-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- AXUFUWARAAYMCG-UHFFFAOYSA-N 3-methylsulfonylpropyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCCS(C)(=O)=O)C=C1 AXUFUWARAAYMCG-UHFFFAOYSA-N 0.000 description 1
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 1
- ZFBKYGFPUCUYIF-UHFFFAOYSA-N 4-amino-2-chlorobenzonitrile Chemical compound NC1=CC=C(C#N)C(Cl)=C1 ZFBKYGFPUCUYIF-UHFFFAOYSA-N 0.000 description 1
- MXJQJURZHQZLNN-UHFFFAOYSA-N 4-amino-2-fluorophenol Chemical compound NC1=CC=C(O)C(F)=C1 MXJQJURZHQZLNN-UHFFFAOYSA-N 0.000 description 1
- RGHJWZADAWEIFE-UHFFFAOYSA-N 4-amino-2-methylbenzonitrile Chemical compound CC1=CC(N)=CC=C1C#N RGHJWZADAWEIFE-UHFFFAOYSA-N 0.000 description 1
- RHHIQBABPRZALH-UHFFFAOYSA-N 4-isothiocyanato-2-methylbenzonitrile Chemical compound CC1=CC(N=C=S)=CC=C1C#N RHHIQBABPRZALH-UHFFFAOYSA-N 0.000 description 1
- GDOIKKMNCIMDAO-UHFFFAOYSA-N 5-amino-1h-pyridin-2-one Chemical compound NC1=CC=C(O)N=C1 GDOIKKMNCIMDAO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- MSDNIFRUGJFOGS-UHFFFAOYSA-N CC(C)(C#N)Nc(cc1)ccc1O Chemical compound CC(C)(C#N)Nc(cc1)ccc1O MSDNIFRUGJFOGS-UHFFFAOYSA-N 0.000 description 1
- ZCIOAQKYEGDSKV-UHFFFAOYSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)cc(F)c1OC Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)cc(F)c1OC ZCIOAQKYEGDSKV-UHFFFAOYSA-N 0.000 description 1
- UERHJZZGHPMCLS-UHFFFAOYSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)cc(F)c1OC(CN(C1)C(C)=O)C1O Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)cc(F)c1OC(CN(C1)C(C)=O)C1O UERHJZZGHPMCLS-UHFFFAOYSA-N 0.000 description 1
- IFPDSCNYTZJFLB-UHFFFAOYSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)cc(F)c1OC(CNC1)C1OC Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)cc(F)c1OC(CNC1)C1OC IFPDSCNYTZJFLB-UHFFFAOYSA-N 0.000 description 1
- GEKGAHBYCAZVSC-UHFFFAOYSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)cc(F)c1Oc(cccc1)c1C(O)=O Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)cc(F)c1Oc(cccc1)c1C(O)=O GEKGAHBYCAZVSC-UHFFFAOYSA-N 0.000 description 1
- KRBMOYIWQCZVHA-UHFFFAOYSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)ccc1OCC(CO)O Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)ccc1OCC(CO)O KRBMOYIWQCZVHA-UHFFFAOYSA-N 0.000 description 1
- KRBMOYIWQCZVHA-INIZCTEOSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)ccc1OC[C@H](CO)O Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)ccc1OC[C@H](CO)O KRBMOYIWQCZVHA-INIZCTEOSA-N 0.000 description 1
- ZBMAWJNDDDAKLG-RTBURBONSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)ccc1O[C@H](COC1)[C@@H]1O Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1)ccc1O[C@H](COC1)[C@@H]1O ZBMAWJNDDDAKLG-RTBURBONSA-N 0.000 description 1
- KKORXYAALDGUST-UHFFFAOYSA-N CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1F)ccc1OC1COC(C)(C)OC1 Chemical compound CC(C)(C(N(C1=S)c(cc2C(F)(F)F)ccc2C#N)=O)N1c(cc1F)ccc1OC1COC(C)(C)OC1 KKORXYAALDGUST-UHFFFAOYSA-N 0.000 description 1
- RIOKPEBUTRGTEA-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1OS(c1ccc(C)cc1)(=O)=O)=O Chemical compound CC(C)(C)OC(N(C1)CC1OS(c1ccc(C)cc1)(=O)=O)=O RIOKPEBUTRGTEA-UHFFFAOYSA-N 0.000 description 1
- BFIOEOUXIHIYAQ-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1Oc(ccc(N(C(C)(C)C(N1c(cc2C(F)(F)F)ccc2C#N)=O)C1=S)c1)c1F)=O Chemical compound CC(C)(C)OC(N(C1)CC1Oc(ccc(N(C(C)(C)C(N1c(cc2C(F)(F)F)ccc2C#N)=O)C1=S)c1)c1F)=O BFIOEOUXIHIYAQ-UHFFFAOYSA-N 0.000 description 1
- HPGWEDDMCGZIGK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1O)CC1Oc(ccc(N(C(C)(C)C(N1c(cc2C(F)(F)F)ccc2C#N)=O)C1=S)c1)c1F)=O Chemical compound CC(C)(C)OC(N(CC1O)CC1Oc(ccc(N(C(C)(C)C(N1c(cc2C(F)(F)F)ccc2C#N)=O)C1=S)c1)c1F)=O HPGWEDDMCGZIGK-UHFFFAOYSA-N 0.000 description 1
- CGNOMSJAJQUXAT-UHFFFAOYSA-N CC(C)(OC1)OCC1O Chemical compound CC(C)(OC1)OCC1O CGNOMSJAJQUXAT-UHFFFAOYSA-N 0.000 description 1
- NLNHVVVDZRCBTH-UHFFFAOYSA-N CC(C)(OC1)OCC1OS(c1ccc(C)cc1)(=O)=O Chemical compound CC(C)(OC1)OCC1OS(c1ccc(C)cc1)(=O)=O NLNHVVVDZRCBTH-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 101150076104 EAT2 gene Proteins 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009167 androgen deprivation therapy Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- VANHFKZRRPSKQW-UHFFFAOYSA-N butyl n-cyanocarbamate Chemical compound CCCCOC(=O)NC#N VANHFKZRRPSKQW-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000001726 chromosome structure Anatomy 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- RZZFOJKGQIYSBE-UHFFFAOYSA-N cyclopropyl carbamate Chemical compound NC(=O)OC1CC1 RZZFOJKGQIYSBE-UHFFFAOYSA-N 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- PAILVKQSHRJIPE-UHFFFAOYSA-N ethyl 1-(hydroxymethyl)cyclopropane-1-carboxylate Chemical compound CCOC(=O)C1(CO)CC1 PAILVKQSHRJIPE-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- JHHMSRLTZAUMOJ-UHFFFAOYSA-N methanamine;oxolane Chemical compound NC.C1CCOC1 JHHMSRLTZAUMOJ-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- PKAHQJNJPDVTDP-UHFFFAOYSA-N methyl cyclopropanecarboxylate Chemical compound COC(=O)C1CC1 PKAHQJNJPDVTDP-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 description 1
- 229960002776 pipamperone Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- NXZIGGBPLGAPTI-UHFFFAOYSA-N tert-butyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2OC21 NXZIGGBPLGAPTI-UHFFFAOYSA-N 0.000 description 1
- LRHQXZMFPRDUBF-UHFFFAOYSA-N tert-butyl N-cyanocarbamate Chemical compound CC(C)(C)OC(=O)NC#N LRHQXZMFPRDUBF-UHFFFAOYSA-N 0.000 description 1
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 1
- KXCHPVKFYPAGIL-UHFFFAOYSA-N tert-butyl-cyclopropyloxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OC1CC1 KXCHPVKFYPAGIL-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- YODQQARABJQLIP-UHFFFAOYSA-N thian-4-ol Chemical compound OC1CCSCC1 YODQQARABJQLIP-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- NTJPIRDYMVYFNP-UHFFFAOYSA-M trimethylsilylmethanesulfonate Chemical compound C[Si](C)(C)CS([O-])(=O)=O NTJPIRDYMVYFNP-UHFFFAOYSA-M 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a novel class of imidazoline derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same, and as therapeutic agents, particularly as androgen receptor antagonists, and in the preparation and treatment of diseases such as prostate cancer Use in medicine. Background technique
- Prostate cancer is the most common cancer in Western men, and the high incidence makes it the third leading cause of cancer death. According to global cancer statistics, the incidence of prostate cancer in men reached more than 900,000 in 2008, second only to lung cancer and bronchial cancer (1,095,200), and the mortality rate was nearly 260,000, accounting for about 6% of total cancer mortality. %.
- PSA prostate specific antigen
- Most prostate cancer patients are effective for androgen deprivation therapy (ADT) for a certain period of time. The main mechanism is to reduce the level of androgen, which can block or reduce the androgen receptor (AR) of prostate cancer. ), thereby inhibiting the activation of androgen-dependent signaling pathways.
- ADT androgen deprivation therapy
- AR signaling is essential for the development and progression of prostate cancer.
- Patients with androgenetic dull syndrome and spinal cord dystrophy lack of A signaling pathways or weak AR signals can cause prostate dysplasia and no cancer.
- HRPC hormone-resistant prostate cancer
- a and its signaling pathway remain intact.
- Genetic and epigenetic genetic variation indicates that AR growth signals in prostate tumors remain active, and therefore, they remain the target of "hormone” therapy. New therapeutic strategies and new drugs block A signals more effectively, producing extremely effective clinical results.
- the AR gene is located on chromosome Xqll-12 and belongs to the family of steroid receptors in the ligand-activated nuclear transcription factor superfamily. AR contains four functional regions: N-terminal transcriptional activation region (AF-1 site), DNA binding region (containing two zinc finger structures), hinge region (containing nuclear localization signal) and C-terminal ligand binding region (AF- 2 sites). Normally, AR is combined with heat shock proteins (HSPs) 90, 70, 56 and 23 in the cytosol to form a stable tertiary structure suitable for androgen binding.
- HSPs heat shock proteins
- HSPs When androgen binds to AR, HSPs dissociate from A, free A dimerizes, then tyrosine kinase phosphorylates, A enters the nucleus, binds to androgen response elements, and is located at the target gene promoter and enhancer sites.
- the androgen response element recruits a co-regulatory protein and forms an active transcriptional complex.
- the co-regulated protein forms a bridge between AR, pre-start complex, and R A polymerase.
- Co-activators can recruit protein complexes to DNA, alter chromosome structure, and form a transcriptionally activated conformation that promotes gene transcription. The co-inhibitor mediates the compression of the chromosome and silences the transcription.
- AR gene amplification occurs in 25%-30% of HRPC patients, and the AR gene amplification rate of patients with initial prostate cancer is very low (1%-2%), suggesting that AR gene amplification is associated with the development of HRPC.
- a gene amplification There is a strong selection pressure for sustained A-signal development during tumor development in androgen deprivation, and provides the impetus for the development of more effective A-signal suppression. Point A mutations alter the specificity of the ligand, for example, the mutated protein A can be activated by non-androgen ligands such as antiandrogen factors.
- Bicalutamide (trade name: Constance) is the most commonly used antiandrogen, although it has an inhibitory effect on A in hormone-sensitive prostate cancer, but when cancer becomes hormone-resistant, bicalutamide cannot Effectively inhibit the activity of A.
- the new androgen receptor antagonist MDV-3100 developed by Medibation can effectively inhibit the binding of androgen to protein A, block the nuclear entry of AR and the recruitment of co-activators of ligand-receptor complexes. At the same time, it has not been found that it will be converted into an agonist in A overexpressing tumors to promote tumor growth. On May 21, 2012, the MDV-3100 entered the pre-registration phase.
- the object of the present invention is to provide a compound represented by the formula (I), and tautomers, mesomers, racemates, enantiomers, diastereomers thereof, Mixture forms and pharmaceutically acceptable salts, as well as metabolites and metabolic precursors or prodrugs.
- A is -CR' or N
- R' is a hydrogen atom, a halogen, an alkyl group, a cycloalkyl group or a heterocyclic group, wherein the alkyl group, the cycloalkyl group or the heterocyclic group are each independently optionally further one or more selected from the group consisting of halogen, cyano group, Substituted by a substituent of a hydroxyl group, an alkyl group, an alkoxy group, a carboxyl group or a carboxylate group;
- Z 1 or Z 2 are each independently alkyl; or Z 1 and Z 2 together with the C atom to which they are attached form a cycloalkyl or heterocyclic group;
- R 1 or R 2 are each independently selected from S or 0;
- R 3 is selected from an alkyl group, an alkenyl group, a blocked group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group or -S(0) m R 6 , wherein the alkenyl group, a blocked group, a cycloalkyl group,
- the heterocyclyl, aryl or heteroaryl are each independently optionally further selected from one or more selected from the group consisting of halogen, cyano, amino, alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl Base, heteroaryl, -OR 6 , -C(0)NR 7 R 8 , -S(0) m R 6 , -C(0)R 6 , -OC(0)R 6 , -NR 7 C( Substituting a substituent of R 8 , —NR 7 C(0)OR 8 or —C(0)OR 6 ; wherein the alkyl group
- R 4 or R 5 are each independently selected from cyano, nitro, alkyl, haloalkyl, hydroxy, halogen, alkoxy or haloalkoxy;
- R 6 is a hydrogen atom, an alkyl group, an alkenyl group, a blocked group, a hydroxyl group, a halogen, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the alkoxy group, the ring group
- the alkyl, heterocyclyl, aryl or heteroaryl are each independently optionally further selected from one or more selected from the group consisting of halogen, cyano, hydroxy, amino, oxo, alkyl, haloalkyl, hydroxyalkyl, alkane Substituted by a substituent of an oxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, a carboxyl group or a carboxylate group;
- R 7 or R 8 are each independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, cycloalkyl group, heterocyclic group, aryl group or hetero group
- the aryl groups are each independently optionally further selected from one or more selected from the group consisting of halogen, cyano, hydroxy, amino, oxo, alkyl, haloalkyl, hydroxyalkyl, alkoxy, cycloalkyl, heterocyclyl, Substituted with a substituent of an aryl, heteroaryl, carboxy or carboxylate group;
- n 0, 1, or 2.
- a compound of the formula (I) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer And mixtures thereof, and pharmaceutically acceptable salts thereof which are compounds of the formula ( ⁇ ) or tautomers, meso, racemates, enantiomers thereof, Diastereomers, salts:
- R' is a hydrogen atom or a halogen
- ⁇ , ⁇ 2 , ⁇ are as defined in the formula (I).
- a compound of the formula (I) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer a construct, a mixture thereof, and a pharmaceutically acceptable salt thereof wherein each of Z 1 or Z 2 is independently methyl.
- a compound of the formula (I) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer a form, a mixture thereof, and a pharmaceutically acceptable salt thereof wherein R 3 is selected from alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein said cycloalkyl, heterocyclic,
- the aryl or heteroaryl are each independently optionally further selected from one or more selected from the group consisting of halogen, amino, alkyl, -OR 6 , -C(0)NR 7 R 8 , -S(0) m R 6 -C Substituting (0) a substituent of R 6 or -C(0)OR 6 wherein the alkyl group is further one or more selected from the group consisting of halogen, cyano, amino, cycloalkyl, heterocyclic, aryl Substituted by a substituent of a heteroaryl
- R 6 R 7 or R 8 are each independently selected from a hydrogen atom or an alkyl group, wherein the alkyl group is optionally further one or more selected from the group consisting of halogen, cyano, hydroxy, amino, oxo, alkyl, Substituted by a substituent of a haloalkyl group;
- n is 2.
- a compound of the formula (I) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer And a mixture thereof wherein R 3 is an alkyl group, the alkyl group further further selected from one or more selected from the group consisting of halogen, cyano, amino, cycloalkyl, heterocyclic Substituted with a substituent of an aryl group, a heteroaryl group, -OR 6 , -C(0)NR 7 R 8 , -S(0) m R 6 or -C(0)OR 6 ;
- R 6 R 7 or R 8 are each independently selected from a hydrogen atom or an alkyl group, wherein the alkyl group is optionally further one or more selected from the group consisting of halogen, cyano, hydroxy, amino, oxo, alkyl, Substituted by a substituent of a haloalkyl group;
- n 2 ⁇ (2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethy
- a compound of the formula (I) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer And a mixture thereof wherein R 3 is a heterocyclic group, the heterocyclic group optionally further selected from one or more selected from the group consisting of halogen, amino, alkyl, -OR 6 , Substituted by a substituent of -C(0)NR 7 R 8 , -S(0) m R 6 -C(0)R 6 or -C(0)OR 6 ; RR 7 or R 8 are each independently selected from hydrogen Atom or alkyl;
- Typical compounds of the invention include, but are not limited to:
- a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer, a mixture thereof, and a pharmaceutically acceptable salt thereof also provides an intermediate for synthesizing a compound, as described above, the compounds la la, 13a, 19b, 31a, 33b, 46b, 6b, 27a, 35d, 37a, 38d, 42b 43c, 44a 45a, 48a, which can be synthesized An intermediate of the corresponding compound.
- 11a can be used as an intermediate for the synthesis of compound 11
- 13a can be used as an intermediate for the synthesis of compound 13, and so on.
- the present invention relates to a compound of the above formula (I) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer thereof, And mixtures thereof, and pharmaceutically acceptable salts thereof
- the compound of the formula (IA) and the compound of the formula (IB) are reacted under basic conditions to give a compound of the formula (I): wherein: LG is a leaving group, preferably a halogen or p-toluenesulfonyloxy group; A, Z
- LG is a leaving group, preferably a halogen or p-toluenesulfonyloxy group;
- A Z
- the definition of ⁇ Z ⁇ 11 5 is as described in the general formula (I).
- the present invention relates to a compound of the above formula (I) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer thereof, And a method of the mixture thereof, and a pharmaceutically acceptable salt thereof, the method comprising the steps of:
- A, Z ⁇ Z ⁇ 11 5 are as defined in the general formula (I).
- the invention relates to a general formula ( ⁇
- R' is a hydrogen atom, a halogen, an alkyl group, a cycloalkyl group or a heterocyclic group, wherein the alkyl group, the cycloalkyl group or the heterocyclic group are each independently optionally further one or more selected from the group consisting of halogen, cyano group, Substituted by a substituent of a hydroxyl group, an alkyl group, an alkoxy group, a carboxyl group or a carboxylate group; R' is preferably a hydrogen atom or a halogen;
- Z 1 or Z 2 are each independently alkyl; or Z 1 and Z 2 together with the C atom to which they are attached form a cycloalkyl or heterocyclic group;
- R 1 or R 2 are each independently selected from S or 0;
- R 4 or R 5 are each independently selected from cyano, nitro, alkyl, haloalkyl, hydroxy, halogen, alkoxy or haloalkoxy.
- the present invention relates to a compound represented by the formula ( ⁇ ) as described above or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer thereof, And mixtures thereof, and pharmaceutically acceptable salts thereof
- the compound of the formula (IA) and the compound of the formula (IB) are reacted under basic conditions to give a compound of the formula ( ⁇ ); wherein: LG is a leaving group, preferably a halogen or p-toluenesulfonyloxy group; A, Z ⁇ Z R', Ri ⁇ R 5 are as defined in the general formula (I).
- the present invention relates to a compound represented by the above formula ( ⁇ ) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer thereof, And mixtures thereof, and pharmaceutically acceptable salts thereof
- A, ZZ 2 , R', ⁇ 11 5 are as defined in the general formula (I).
- another aspect of the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula (I) or a tautomer thereof, a mesogen, a racemate, a pair Isomers, diastereomers, mixtures, and pharmaceutically acceptable salts thereof, and pharmaceutically acceptable carriers, diluents or excipients thereof.
- Another aspect of the invention relates to a compound of the formula (I) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer, a mixture, And use of a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, in the preparation of an androgen receptor modulator.
- Another aspect of the invention relates to a compound of the formula (I) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer, a mixture, And use of a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, in the preparation of an androgen receptor antagonist.
- Another aspect of the invention relates to a compound of the formula (I) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer, a mixture, And a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, which acts as a drug for regulating androgen receptor activity; preferably as a drug which antagonizes androgen receptor activity.
- Another aspect of the invention relates to a method of modulating androgen receptor activity, preferably a method of antagonizing androgen receptor activity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or A tautomer, a meso form, a racemate, an enantiomer, a diastereomer, a mixture, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
- a compound of formula (I) or A tautomer a meso form, a racemate, an enantiomer, a diastereomer, a mixture, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
- Another aspect of the invention relates to a compound of the formula (I) or a tautomer thereof, a mesogen, an external a racemate, an enantiomer, a diastereomer, a mixture, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same for the preparation of a medicament for treating or preventing a condition mediated by androgen receptor
- the androgen receptor mediated condition is selected from the group consisting of prostate cancer, benign prostatic hyperplasia, hirsutism, alopecia, anorexia nervosa, breast cancer, acne, male sexual dysfunction, AIDS or cachexia, preferably mammary gland
- the cancer or prostate cancer is more preferably prostate cancer, and most preferably hormone sensitive prostate cancer or hormone refractory prostate cancer.
- Another aspect of the invention relates to a method of treating or preventing a condition mediated by androgen receptor, wherein the condition mediated by the androgen receptor is selected from the group consisting of prostate cancer, benign prostatic hyperplasia, hirsutism, alopecia, anorexia nervosa, A breast cancer, acne, male sexual dysfunction, AIDS or cachexia condition, preferably breast cancer or prostate cancer, more preferably prostate cancer, most preferably hormone sensitive prostate cancer or hormone refractory prostate cancer, the method comprising administering A therapeutically effective amount of a compound of the formula (I) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer, a mixture thereof, in a patient in need of treatment And a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
- the condition mediated by the androgen receptor is selected from the group consisting of prostate cancer, benign prostatic hyperplasia, hirsutism,
- Another aspect of the invention relates to a compound of the formula (I) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer, a mixture, And a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, which is a medicament for treating or preventing a condition mediated by an androgen receptor, wherein the condition mediated by androgen receptor is selected from the group consisting of prostate cancer, benign prostatic hyperplasia, and hairy Symptoms, alopecia, anorexia nervosa, breast cancer, acne, male sexual dysfunction, AIDS or cachexia, preferably breast or prostate cancer, more preferably prostate cancer, most preferably hormone-sensitive prostate cancer or hormone Governance of prostate cancer.
- Another aspect of the invention relates to a compound of the formula (I) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer, a mixture, And use of a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, in the manufacture of a medicament for use in male contraception.
- Another aspect of the invention relates to a compound of the formula (I) or a tautomer, a mesogen, a racemate, an enantiomer, a diastereomer, a mixture, And a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, which is used as a medicament for male contraception.
- Another aspect of the invention relates to a method of contraception in a male comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a tautomer thereof, a mesogen, a racemic a body, an enantiomer, a diastereomer, a mixture, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
- a compound of formula (I) or a tautomer thereof a mesogen, a racemic a body, an enantiomer, a diastereomer, a mixture, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
- Alkyl means a saturated aliphatic hydrocarbon group including straight chain and branched chain groups of 1 to 20 carbon atoms. Optimal An alkyl group having 1 to 10 carbon atoms, more preferably an alkyl group having 1 to 6 carbon atoms.
- Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2 -methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl,
- lower alkyl groups having 1 to 6 carbon atoms More preferred are lower alkyl groups having 1 to 6 carbon atoms, and non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, sec-butyl Base, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethyl Butyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl Base, 2,3-dimethylbutyl and the like.
- the alkyl group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, preferably one or more of the following groups, independently selected from alkyl, alkenyl, Block, alkoxy, alkylthio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycle Alkoxy, cycloalkylthio, heterocycloalkylthio, oxo, -OR 6 , -NR 7 R 8 , -C(0)NR 7 R 8 -S(0) m R 6 -C(0) R 6 , -OC(0)R 6 , -NR 7 C(0)R 8 , -NR 7 C(0)OR 8 or -C(0)OR 6 .
- Cycloalkyl means a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent comprising from 3 to 20 carbon atoms, preferably from 3 to 12 carbon atoms, more preferably the cycloalkyl ring comprises from 3 to 10 The carbon atom, most preferably the cycloalkyl ring contains from 3 to 6 carbon atoms.
- Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene Alkenyl, cyclooctyl and the like.
- Polycyclic cycloalkyl groups include spiro, fused, and bridged cycloalkyl groups.
- Spirocycloalkyl means a polycyclic group of 5 to 20 members which shares a carbon atom (referred to as a spiro atom) between the monocyclic rings. These may contain one or more double bonds, but none of the rings are fully conjugated. ⁇ electronic system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- the spirocycloalkyl group is classified into a monospirocycloalkyl group, a bispirocycloalkyl group or a polyspirocycloalkyl group, preferably a monospirocycloalkyl group and a bispirocycloalkyl group, depending on the number of common spiro atoms between the ring and the ring.
- spirocycloalkyl groups include "Fused cycloalkyl" means 5 to 20 members, each ring of the system sharing an adjacent carbon atom of an all-carbon polycyclic group with other rings in the system, wherein one or more rings may contain one or more Two double bonds, but none of the rings have a fully conjugated ⁇ -electron system.
- Bridge cycloalkyl means 5 to 20 members, any two rings sharing two carbon-free all-carbon polycyclic groups, which may contain one or more double bonds, but none of the rings have a total The ⁇ electronic system of the yoke. It is preferably 6 to 14 members, more preferably 7 to 10 members. Depending on the number of constituent rings, it may be classified into a bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl group, preferably a bicyclic ring, a tricyclic ring or a tetracyclic ring, and more preferably a bicyclic ring or a tricyclic ring. Bridged cycloalkyl
- the cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring to which the parent structure is attached is a cycloalkyl group, non-limiting examples include indanyl, tetrahydrogen Naphthyl, benzocycloheptyl and the like.
- the cycloalkyl group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, block, alkoxy, alkylthio Base, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, Heterocycloalkylthio, oxo, -OR 6 , -NR 7 R 8 , -C(0)NR 7 R 8 , -S(0) m R 6 , -C(0)R 6 , -OC(0 R 6 , -NR 7 C(0)R 8 , -NR 7 C(0)OR 8 or -C(0)OR 6 .
- Heterocyclyl means a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent comprising from 3 to 20 ring atoms wherein one or more of the ring atoms are selected from nitrogen, oxygen or S(0) m ( Wherein m is a hetero atom of the integer 0 to 2), but does not include a ring moiety of -0-0-, -0-S- or -SS-, and the remaining ring atoms are carbon.
- Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl, tetrahydrofuranyl, 1,1- Dioxo-tetrahydrothiopyranyl, oxetanyl, azetidinyl and the like.
- the polycyclic heterocyclic group includes a spiro ring, a fused ring, and a heterocyclic group of a bridged ring.
- spiroheterocyclyl means a polycyclic heterocyclic group of 5 to 20 members in which one atom (called a spiro atom) is shared between monocyclic rings.
- One or more of the ring atoms are selected from the group consisting of nitrogen, oxygen or S(0) m (where m is an integer from 0 to 2), and the remaining ring atoms are carbon. These may contain one or more double bonds, but none of the rings have a fully conjugated pi-electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- the spirocycloalkyl group is classified into a monospiroheterocyclic group, a dispirocyclic heterocyclic group or a polyspirocyclic group according to the number of the shared spiro atoms between the ring and the ring, and is preferably a monospiroheterocyclic group and a dispiroheterocyclic group. More preferably, it is 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6-membered monospiroheterocyclic group.
- “Fused heterocyclic group” means 5 to 20 members, each ring in the system shares an adjacent pair of atomic polycyclic heterocyclic groups with other rings in the system, and one or more rings may contain one or more a bond, but none of the rings have a fully conjugated ⁇ -electron system in which one or more ring atoms are selected from nitrogen, oxygen or S(0) m (where m is an integer from 0 to 2), and the remaining ring atoms are carbon. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- fused heterocyclic groups include
- “Bridge heterocyclyl” refers to a polycyclic heterocyclic group of 5 to 14 members in which two rings share two atoms which are not directly bonded, and these may contain one or more double bonds, but none of the rings have a complete conjugation A ⁇ -electron system in which one or more ring atoms are selected from nitrogen, oxygen or S(0) m (where m is an integer from 0 to 2), and the remaining ring atoms are carbon. It is preferably 6 to 14 members, more preferably 7 to 10 members. 7 to 10 yuan. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic,
- the heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring wherein the ring to which the parent structure is attached is a heterocyclic group, non-limiting examples comprising:
- the heterocyclic group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, independently selected from the group consisting of alkyl, alkenyl, block, alkoxy, alkylthio Base, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, Heterocycloalkylthio, oxo, -OR 6 , -NR 7 R 8 , -C(0)NR 7 R 8 -S(0) m R 6 -C(0)R 6 , -OC(0)R 6 , -NR 7 C(0)R 8 , -NR 7 C(0)OR 8 or -C(0)OR 6 .
- Aryl means a 6 to 14 membered all-carbon monocyclic or fused polycyclic ring (ie, a ring sharing a pair of adjacent carbon atoms) having a conjugated ⁇ -electron system, preferably a 6 to 10 membered aryl group, More preferred are phenyl and naphthyl, and most preferred is phenyl.
- the aryl ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring wherein the ring to which the parent structure is attached is an aryl ring, non-limiting examples comprising:
- the aryl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, independently selected from the group consisting of alkyl, alkenyl, block, alkoxy, alkylthio, alkane.
- Heteroaryl refers to a 5- to 14-membered all-carbon monocyclic or fused polycyclic group having a conjugated ⁇ -electron system, further comprising from 1 to 4 heteroatoms, wherein the heteroatoms are selected from one or more oxygen , sulfur or nitrogen. It is preferably a 5- to 10-membered heteroaryl group, more preferably a 5- to 6-membered heteroaryl group, even more preferably a furyl group, a thienyl group, a pyridyl group, a pyrrolyl group, a fluorenyl-alkylpyrrolyl group, a pyrimidinyl group, and a pyridyl group.
- heteroaryl ring may be fused to an aryl group, a heterocyclic group or a cycloalkyl ring, wherein the ring bonded to the parent structure is hetero
- the heteroaryl group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably a group of one or less, independently selected from the group consisting of an alkyl group, an alkenyl group, a blocked group, an alkoxy group, and an alkylthio group.
- alkenyl refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, preferably a C 2 -6 alkenyl group, more preferably a C 2 _ 4 alkenyl group.
- a vinyl group a 1-propenyl group, a 2-propenyl group, a 1-, 2- or 3-butenyl group, and the like.
- the alkenyl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, block, alkoxy, alkylthio, Alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio, oxo, -OR 6 , -NR 7 R 8 , -C(0)NR 7 R 8 -S(0) m R 6 -C(0)R 6 , -OC(0)R 6 , -NR 7 C(0)R 8 , -NR 7 C(0)OR 8 or -C(0)OR 6 .
- block group refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, preferably a C 2 -6 block group, more preferably a C 2 _ 4 block group.
- a C 2 -6 block group preferably a C 2 _ 4 block group.
- the block group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, block, alkoxy, alkylthio, Alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio, oxo, -OR 6 , -NR 7 R 8 , -C(0)NR 7 R 8 -S(0) m R 6 -C(0)R 6 , -OC(0)R 6 , -NR 7 C(0)R 8 , -NR 7 C(0)OR 8 or -C(0)OR 6 .
- Alkoxy means -o-(alkyl) and -o-(unsubstituted cycloalkyl), wherein alkyl, cycloalkyl are as defined above. Non-limiting examples include methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy and the like.
- the alkoxy group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, independently selected from the group consisting of an alkyl group, an alkenyl group, a block group, an alkoxy group, and an alkane group.
- Haldroxyalkyl means -(fluorenyl)-OH, wherein alkyl is as defined above
- Haloalkyl means an alkyl group substituted by one or more halogens, wherein alkyl is as defined above.
- Haldroxy means an -OH group.
- Halogen means fluoro, chloro, bromo or iodo.
- Amino means -NH 2 .
- Neitro means -N0 2 .
- Carboxy means -C(0)OH.
- the "carboxylate group” means -C(0)0(alkyl) or (cycloalkyl), wherein the alkyl group and the cycloalkyl group are as defined above.
- heterocyclic group optionally substituted by an alkyl group means that an alkyl group may be, but not necessarily, present, including the case where the heterocyclic group is substituted by an alkyl group and the case where the heterocyclic group is not substituted by an alkyl group.
- Substituted means one or more hydrogen atoms in the group, preferably up to 5, more preferably 1 to 3, hydrogen atoms are independently substituted with each other by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art will be able to determine (by experiment or theory) substitutions that may or may not be possible without undue effort. For example, an amino or hydroxyl group having a free hydrogen may be unstable when combined with a carbon atom having an unsaturated (e.g., olefinic) bond.
- “Pharmaceutical composition” means a mixture containing one or more of the compounds described herein, or a physiologically/pharmaceutically acceptable salt or prodrug thereof, and other chemical components, as well as other components such as physiological/pharmaceutically acceptable carriers. And excipients.
- the purpose of the pharmaceutical composition is to promote the administration of the organism, which facilitates the absorption of the active ingredient and thereby the biological activity.
- the method includes the following steps:
- the reaction is carried out to obtain a cyano compound (c); the aniline compound (d) is reacted with sulfur phosgene in a solvent to obtain an isothiocyanobenzene ring compound (e); the isothiocyanatobenzene compound (e) is in a solvent with cyanogen
- the base compound (c) is subjected to a cyclization reaction and hydrolyzed under acidic conditions to obtain a thioimidazoline compound (f); the thioimidazoline compound (f) is substituted with a LG-substituted R 3 compound in a solvent under basic conditions (g)
- the reaction gives a compound of the formula (I). Wherein LG is a leaving group, preferably a halogen or p-toluenesulfonyloxy group; and A, ZZ 2 , and ⁇ 11 5 are as defined in the formula (I).
- the reagents for acidic conditions include, but are not limited to, trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid or methanesulfonic acid, preferably hydrochloric acid.
- Basic conditions include organic bases and inorganic bases including, but not limited to, triethylamine, N,N-diisopropylethylamine, N,N-dimethylformamide, n-butyl Lithium, potassium t-butoxide or tetrabutylammonium bromide; said inorganic bases including but not limited to sodium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, potassium hydrogencarbonate or carbonic acid ⁇ , preferably cesium carbonate, potassium carbonate or potassium hydroxide.
- Solvents used include, but are not limited to, acetic acid, ethanol, tetrahydrofuran, dimethyl sulfoxide, 1,4-dioxane, n-hexane, acetone, methanol, water, acetonitrile, dichloromethane, toluene, N, N-dimethyl Carboxamide or N,N-dimethylacetamide.
- an azodicarboxylic acid derivative preferably i,r-(azodicarboxylic acid)
- dipiperidine or diisopropyl azodicarboxylate a condensation reaction occurs to give a compound of the formula (I).
- ⁇ , ⁇ ⁇ 1 ⁇ 1 5 are as defined in the general formula (I).
- Basic conditions include organic bases and inorganic bases including, but not limited to, triethylamine, N,N-diisopropylethylamine, N,N-dimethylformamide, n-butyl Lithium, potassium t-butoxide or tetrabutylammonium bromide; said inorganic bases including but not limited to sodium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, potassium hydrogencarbonate or carbonic acid ⁇ , preferably cesium carbonate, potassium carbonate or potassium hydroxide.
- Solvents used include, but are not limited to, acetic acid, ethanol, tetrahydrofuran, dimethyl sulfoxide, 1,4-dioxane, n-hexane, acetone, methanol, water, acetonitrile, dichloromethane, toluene, N, N-dimethyl Carboxamide or N,N-dimethylacetamide.
- acetic acid ethanol
- tetrahydrofuran dimethyl sulfoxide
- 1,4-dioxane 1,4-dioxane
- n-hexane acetone
- methanol acetone
- water acetonitrile
- dichloromethane toluene
- N, N-dimethyl Carboxamide or N,N-dimethylacetamide.
- Basic conditions include organic bases and inorganic bases including, but not limited to, triethylamine, N,N-diisopropylethylamine, N,N-dimethylformamide, n-butyl Lithium, potassium t-butoxide or tetrabutylammonium bromide; the inorganic bases include, but are not limited to, sodium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogencarbonate, Potassium carbonate, potassium hydrogencarbonate or cesium carbonate, preferably cesium carbonate, potassium carbonate or potassium hydroxide.
- Solvents used include, but are not limited to, acetic acid, ethanol, tetrahydrofuran, dimethyl sulfoxide, 1,4-dioxane, n-hexane, acetone, methanol, water, acetonitrile, dichloromethane, toluene, N, N-dimethyl Carbamide or hydrazine, hydrazine-dimethylacetamide.
- the amino compound (Ila) is reacted with a ketone (b) and trimethylcyanosilane in the presence of trimethylsilyl trifluoromethanesulfonate in a solvent to obtain a cyano compound (lie); the aniline compound (d) is in a solvent Sulfur phosgene reaction to obtain isothiocyanobenzene ring compound (e); isothiocyanatobenzene compound (e) is cyclized with cyano compound (lie) in a solvent, and hydrolyzed under acidic conditions to obtain thio An imidazoline compound (Ilf); a thioimidazoline compound ( ⁇ ) is reacted with a LG-substituted R 3 compound (g) in a solvent under basic conditions to give a compound of the formula (II).
- LG is a leaving group, preferably a halogen or p-toluenesulfonyloxy group
- the reagents for acidic conditions include, but are not limited to, trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid or methanesulfonic acid, preferably hydrochloric acid.
- Basic conditions include organic bases and inorganic bases, including but not limited to triethylamine,
- Solvents used include, but are not limited to, acetic acid, ethanol, tetrahydrofuran, dimethyl sulfoxide, 1,4-dioxane, n-hexane, acetone, methanol, water, acetonitrile, dichloromethane, toluene, N, N-dimethyl Carbamide or hydrazine, hydrazine-dimethylacetamide.
- acetic acid ethanol, tetrahydrofuran, dimethyl sulfoxide, 1,4-dioxane, n-hexane, acetone, methanol, water, acetonitrile, dichloromethane, toluene, N, N-dimethyl Carbamide or hydrazine, hydrazine-dimethylacetamide.
- solvents used include, but are not limited to, acetic acid, ethanol, tetrahydrofuran, dimethyl sulfoxide
- an azodicarboxylic acid derivative preferably i,r-(azodicarboxylic acid)
- dipiperidine or diisopropyl azodicarboxylate a condensation reaction occurs to give a compound of the formula ( ⁇ ).
- ZZ 2 , R', 1 ⁇ 1 5 are as defined in the general formula (II).
- Basic conditions include organic bases and inorganic bases including, but not limited to, triethylamine, N,N-diisopropylethylamine, N,N-dimethylformamide, n-butyl Lithium, potassium t-butoxide or tetrabutylammonium bromide; said inorganic bases including but not limited to sodium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, potassium hydrogencarbonate or carbonic acid ⁇ , preferably cesium carbonate, potassium carbonate or potassium hydroxide.
- Solvents used include, but are not limited to, acetic acid, ethanol, tetrahydrofuran, dimethyl sulfoxide, 1,4-dioxane, n-hexane, acetone, methanol, water, acetonitrile, dichloromethane, toluene, N, N-dimethyl Carboxamide or N,N-dimethylacetamide.
- thioimidazoline compound ( ⁇ ) is reacted with 3,4-epoxytetrahydrofuran (i) in a solvent under basic conditions to give a compound of the formula ( ⁇ ).
- ZZ R', RR 2 , R 4 and R 5 are as defined in the general formula (II), and R 3 is 4-hydroxy-tetrahydrofuran.
- Basic conditions include organic bases and inorganic bases, including but not limited to triethylamine,
- Solvents used include, but are not limited to, acetic acid, ethanol, tetrahydrofuran, dimethyl sulfoxide, 1,4-dioxane, n-hexane, acetone, methanol, water, acetonitrile, dichloromethane, toluene, N, N-dimethyl Carboxamide or N,N-dimethylacetamide. detailed description
- the structure of the compound is determined by nuclear magnetic resonance (NMR) or/and mass spectrometry (MS). NMR shifts ([delta]) are given in units of 10- 6 (ppm) a.
- the NMR was measured by a Bruker AVANCE-400 nuclear magnetic apparatus, and the solvent was deuterated dimethyl sulfoxide deuterated chloroform (CDC1 3 ), deuterated methanol (CD 3 OD), and internal standard was tetramethylsilane (CTMS).
- the MS was assayed using a FINMGAN LCQAd (ESI) mass spectrometer (manufacturer: Thermo, model: Finnigan LCQ advantage MAX).
- ESI FINMGAN LCQAd
- the HPLC was measured using an Agilent 1200 DAD high pressure liquid chromatograph (Sunfire C18 150 x 4.6 mm column) and a Waters 2695-2996 high pressure liquid chromatograph (Gimini C18 150 x 4.6 mm column).
- the average inhibition rate of the kinase and the IC 5Q value were determined using a NovoStar plate reader (BMG, Germany).
- the thin layer chromatography silica gel plate uses Yantai Yellow Sea HSGF254 or Qingdao GF254 silica gel plate.
- the silica gel plate used for thin layer chromatography (TLC) has a specification of 0.15 mm ⁇ 0.2 mm, and the thin layer chromatography separation and purification product adopts the specification of 0.4 mm. ⁇ 0.5 mm.
- the known starting materials of the present invention may be synthesized by or according to methods known in the art, or may be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, Companies such as Dare Chemicals.
- Oxone reagent refers to 2KHS0 5 ⁇ KHS0 4 ⁇ K 2 S0 4 .
- reaction can be carried out under an argon atmosphere or a nitrogen atmosphere.
- An argon atmosphere or a nitrogen atmosphere means that the reaction flask is connected to an argon or nitrogen balloon having a volume of about 1 L.
- the hydrogen atmosphere means that the reaction flask is connected to a hydrogen balloon of about 1 L volume.
- the pressurized hydrogenation reaction uses a Parr Model 3916EKX hydrogenation apparatus and a clear blue QL-500 hydrogen generator or a HC2-SS type hydrogenation apparatus.
- the hydrogenation reaction is usually evacuated, charged with hydrogen, and operated three times.
- the solution means an aqueous solution.
- reaction temperature is room temperature and is 20 ° C to 30 ° C.
- the progress of the reaction in the examples was monitored by thin layer chromatography (TLC).
- TLC thin layer chromatography
- the system used for the reaction was: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: petroleum ether And the ethyl acetate system, D: acetone, the volume ratio of the solvent is adjusted depending on the polarity of the compound.
- Purification compounds using column chromatography eluent systems and thin layer chromatography developers include: A: dichloromethane and methanol systems, B: n-hexane and ethyl acetate systems, C: dichloromethane and acetone
- the volume ratio of the solvent to the system is adjusted according to the polarity of the compound. It can also be adjusted by adding a small amount of an alkaline or acidic reagent such as triethylamine and acetic acid, D: n-hexane and dichloromethane system, E: petroleum ether and Ethyl acetate system.
- an alkaline or acidic reagent such as triethylamine and acetic acid
- D n-hexane and dichloromethane system
- E petroleum ether and Eth
- Methyl 1-hydroxycyclopropane 5a (; 350 mg, 3.02 mmol) was dissolved in 30 mL of dichloromethane and tert-butyldimethylchlorosilane (495 mg, 3.30 mmol) and imidazole (306 mg, 4.49). Mm). The reaction was stirred for 12 hours. After adding 20 mL of dichloromethane, it was washed with a saturated sodium chloride solution (20 mL ⁇ 3), dried over anhydrous sodium sulfate, filtered, Methyl cyclopropanoate 5b (600 mg, clear oil) was used for the next step without purification.
- EtOAc EtOAc (EtOAc) (HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
- tert-Butyl 1-(hydroxymethyl)cyclopropanecarbamate 6a (53 mg, 0.28 mmol) was placed in a reaction flask and 4-(3-(3-fluoro-4-hydroxyphenyl)-4 was added sequentially.
- 4-Dimethyl-5-one-2-thioimidazolin-1-yl)-2-(trifluoromethyl)benzonitrile le (100 mg, 0.24 mmol)
- 1, ⁇ -(azodicarboxylate Acid dipiperidine 95 mg, 0.38 mmol
- 5 mL toluene were added tri-n-butylphosphine (76 mg, 0.38 mmol) and allowed to react at 50 ° C for 2 hours.
- Tetrahydro-2H-thiopyran-4-ol 23a (350 mg, 2.97 mmol, prepared by the method disclosed in Patent Application No. 1466898 A1) was placed in a reaction flask, followed by the addition of triethylamine (606 mg, 5.94 mmol). , 4-dimethylaminopyridine (36 mg, 0.30 mmol) and 20 mL of dichloromethane, p-toluenesulfonyl chloride (848 mg, 4.45 mmol) was added, and the reaction was stirred for 12 hours. 30 mL of water was added and the mixture was allowed to stand.
- 4-Amino-2-methylbenzonitrile 38a (110 mg, 0.83 mmol) was dissolved in 5 mL of tetrahydrofuran, cooled to 0 ° C, thiophosgene (115 mg, 0.99 mmol) was added, and reacted at 0 ° C for 1 hour. . Add 20 mL of water with acetic acid The esters were extracted (20 mL ⁇ 3), EtOAc (EtOAc m. Benzonitrile 38b (130 mg, yellow solid), Yield: 89.7%.
- 14c 40a 4-(3-(4-Hydroxyphenyl)-4,4-dimethyl-5-one-2-thioimidazolin-1-yl)-2-(trifluoromethyl)benzene
- the nitrile 14c (100 mg, 0.25 mmol) was dissolved in 5 mL of N,N-dimethylformamide, followed by oxetane-3-yl-4-tosylate 40a (114 mg, 0.50 mmol, Using the well-known method literature "Orgam'c Letters, 2008, 10(15), 3259-3262 "Prepared” and potassium carbonate (103 mg, 0.75 mmol), and allowed to react at 80 ° C for 12 hours.
- test examples of the present invention are usually carried out according to conventional conditions or according to the conditions recommended by the manufacturer of the product.
- Reagents not specified for specific sources are routine reagents purchased by the market.
- Test Example 1 Biological Evaluation of PSA Inhibitory Activity Secreted by LNcap Cells
- LNcap cells Cellular Library of the Culture Collection Committee of the Chinese Academy of Sciences, TCHul 73
- Cell culture medium RIPM 1640 medium, 10% FBS, 1% Pen Strep,
- Activated carbon medium RIPM 1640 medium, 10% CS-FBS, 1% Pen Strep,
- Testosterone medium RIPM 1640 medium, 10% CS-FBS, 1% Pen Strep, InM testosterone
- LNcap cells are subcultured in cell culture medium and resuspended in activated carbon culture medium at a density of 5 X
- the drug was formulated with DMSO (dimethyl sulfoxide) as a 10 mM stock solution. Dilute with DMSO before use After 5 times, it was diluted by a gradient of 3 times to obtain 8 gradient concentrations. Each concentration of the compound was diluted 20-fold with testosterone broth. (To ensure that the DMSO concentration in each culture system is 0.5%), to be tested.
- DMSO dimethyl sulfoxide
- the blank group was supplemented with 5% DMSO diluted with activated carbon medium; the control group was added with 1 ⁇ 5% DMSO diluted with testosterone medium; cultured in a 37 ° C, 5% CO 2 incubator.
- the IC 5Q value of the compound can be calculated from the inhibition rates at different concentrations.
- the experimental procedure is the same as the experimental procedure of Test Example 1.
- the IC 5Q value of the compound can be calculated from the inhibition rates at different concentrations.
- LNcap-AR cells The following in vitro screening assays are used to determine the secretion of a compound of the invention at higher concentrations for LNcap-AR cells (highly expressed in L-caps expressing A-LNcap cells by retroviral transfection, referred to as LNcap-AR cells).
- LNcap-AR cells The agonistic activity of PSA.
- LNcap-AR cells were subcultured with cell culture medium, resuspended in activated carbon culture medium at a density of 5 10 4 cells/1 ⁇ , and seeded in 96-well plates at 100 ul per well.
- the drug was formulated with DMSO (dimethyl sulfoxide) as a 10 mM stock solution. Diluted into 2 mM, 0.6 mM two concentrations before use. The compound of each concentration was diluted 20 times with activated carbon broth (to ensure that the DMSO concentration in each culture system was 0.5%), and was used.
- DMSO dimethyl sulfoxide
- the agonistic activity of the compound for secretion of PSA by LNcap-AR cells was evaluated by the percentage value of the OD value measured for the test compound well and the blank control well. When the percentage value is >100, it indicates that the test compound is empty. Compared with the white control, the LNcap-AR cells have agonistic activity for secreting PSA; on the contrary, when the percentage value is ⁇ 100, the test compound is considered to have no agonistic activity.
- the specific test results are as follows:
- Example 6 Male rats were used as test animals, and the compound of Example 6, the compound of Example 9, the compound of Example 11, the compound of Example 13, the compound of Example 15, and the examples were given by the LC/MS/MS method.
- concentration of the drug in plasma at different times after the compound of Example 16, the compound of Example 17, the compound of Example 44 and the compound of Example 45.
- the pharmacokinetic behavior of the compounds of the present invention in rats was investigated and their pharmacokinetic characteristics were evaluated.
- the content of the test compound in the plasma of rats after intragastric administration of different compounds was determined by LC/MS/MS method.
- the linear range of the method was 1.00 ⁇ 2000 ng/ml; plasma samples were analyzed by methanol precipitation protein analysis.
- the pharmacokinetic parameters of the compounds of the invention are as follows:
- the compound of the present invention has good pharmacological absorption and has obvious pharmacokinetic advantages.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2883545A CA2883545C (en) | 2012-09-04 | 2013-08-26 | Imidazoline derivatives, preparation methods thereof, and their applications in medicine |
MX2015002602A MX368844B (es) | 2012-09-04 | 2013-08-26 | Derivados de imidazolina, métodos de preparación de los mismos, y sus aplicaciones en medicina. |
ES13835193T ES2835248T3 (es) | 2012-09-04 | 2013-08-26 | Derivados de imidazolina, métodos de preparación de los mismos y sus aplicaciones en medicina |
EP13835193.7A EP2894151B1 (en) | 2012-09-04 | 2013-08-26 | Imidazoline derivatives, preparation methods thereof, and their applications in medicine |
SI201331826T SI2894151T1 (sl) | 2012-09-04 | 2013-08-26 | Imidazolinski derivati, postopki za njihovo pripravo in njihove uporabe v medicini |
US14/425,207 US9586947B2 (en) | 2012-09-04 | 2013-08-26 | Imidazoline derivatives, preparation methods thereof, and their applications in medicine |
RS20201565A RS61242B1 (sr) | 2012-09-04 | 2013-08-26 | Derivati imidazolina, postupci njihove pripreme i njihove primene u medicini |
RU2015110122A RU2639145C2 (ru) | 2012-09-04 | 2013-08-26 | Производные оксотиоимидазолидина, способы их получения и их применение в медицине в качестве ингибиторов андрогенного рецептора |
KR1020157007651A KR102189940B1 (ko) | 2012-09-04 | 2013-08-26 | 이미다졸린 유도체, 이의 제조 방법, 및 이들의 의약에서의 용도 |
AU2013312587A AU2013312587B2 (en) | 2012-09-04 | 2013-08-26 | Imidazoline derivatives, preparation methods thereof, and their applications in medicine |
BR112015004637-1A BR112015004637B1 (pt) | 2012-09-04 | 2013-08-26 | Derivados de imidazolina, seus usos e seus processos de preparação, e composição farmacêutica |
CN201380004069.5A CN103958480B (zh) | 2012-09-04 | 2013-08-26 | 咪唑啉类衍生物、其制备方法及其在医药上的应用 |
JP2015528857A JP6262733B2 (ja) | 2012-09-04 | 2013-08-26 | イミダゾリン誘導体、その製造法、およびそれらの医薬への適用 |
LTEP13835193.7T LT2894151T (lt) | 2012-09-04 | 2013-08-26 | Imidazolino dariniai, jų gamybos būdai ir jų naudojimas medicinoje |
DK13835193.7T DK2894151T3 (da) | 2012-09-04 | 2013-08-26 | Imidazolinderivater, fremgangsmåder til fremstilling deraf og anvendelse deraf i medicin |
HK14111978.7A HK1198476A1 (zh) | 2012-09-04 | 2014-11-27 | 咪唑啉類衍生物、其製備方法及其在醫藥上的應用 |
US15/411,517 US9895355B2 (en) | 2012-09-04 | 2017-01-20 | Methods of treating androgen receptor-mediated disorders with imidazoline derivatives |
CY20201101202T CY1123649T1 (el) | 2012-09-04 | 2020-12-18 | Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη |
HRP20202050TT HRP20202050T1 (hr) | 2012-09-04 | 2020-12-21 | Derivati imidazolina, postupci njihove pripreme i njihova medicinska primjena |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210323870 | 2012-09-04 | ||
CN201210323870.3 | 2012-09-04 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/425,207 A-371-Of-International US9586947B2 (en) | 2012-09-04 | 2013-08-26 | Imidazoline derivatives, preparation methods thereof, and their applications in medicine |
US15/411,517 Division US9895355B2 (en) | 2012-09-04 | 2017-01-20 | Methods of treating androgen receptor-mediated disorders with imidazoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014036897A1 true WO2014036897A1 (zh) | 2014-03-13 |
Family
ID=50236528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/082273 WO2014036897A1 (zh) | 2012-09-04 | 2013-08-26 | 咪唑啉类衍生物、其制备方法及其在医药上的应用 |
Country Status (22)
Country | Link |
---|---|
US (2) | US9586947B2 (zh) |
EP (1) | EP2894151B1 (zh) |
JP (1) | JP6262733B2 (zh) |
KR (1) | KR102189940B1 (zh) |
CN (1) | CN103958480B (zh) |
AU (1) | AU2013312587B2 (zh) |
BR (1) | BR112015004637B1 (zh) |
CA (1) | CA2883545C (zh) |
CY (1) | CY1123649T1 (zh) |
DK (1) | DK2894151T3 (zh) |
ES (1) | ES2835248T3 (zh) |
HK (1) | HK1198476A1 (zh) |
HR (1) | HRP20202050T1 (zh) |
HU (1) | HUE052904T2 (zh) |
LT (1) | LT2894151T (zh) |
MX (1) | MX368844B (zh) |
PT (1) | PT2894151T (zh) |
RS (1) | RS61242B1 (zh) |
RU (1) | RU2639145C2 (zh) |
SI (1) | SI2894151T1 (zh) |
TW (1) | TWI617546B (zh) |
WO (1) | WO2014036897A1 (zh) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160214972A1 (en) * | 2015-01-20 | 2016-07-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
WO2017041622A1 (zh) * | 2015-09-10 | 2017-03-16 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的结晶形式及其制备方法 |
CN106518773A (zh) * | 2015-09-10 | 2017-03-22 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的结晶形式及其制备方法 |
WO2017067530A2 (zh) | 2017-02-13 | 2017-04-27 | 康朴生物医药技术(上海)有限公司 | 一种治疗***癌的组合、药物组合物及治疗方法 |
WO2017140253A1 (zh) | 2016-02-19 | 2017-08-24 | 江苏恒瑞医药股份有限公司 | 一种含有咪唑啉类衍生物的药物组合物 |
US10000502B2 (en) | 2016-01-11 | 2018-06-19 | Janssen Pharmaceutica Nv | Substituted thiohydantoin derivatives as androgen receptor antagonists |
CN108976171A (zh) * | 2018-08-27 | 2018-12-11 | 长沙泽达医药科技有限公司 | 化合物、组合物及其在药物制备中的用途 |
CN109912509A (zh) * | 2017-12-13 | 2019-06-21 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的晶型及其制备方法 |
CN110023297A (zh) * | 2016-07-08 | 2019-07-16 | 詹森药业有限公司 | 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物 |
CN110684046A (zh) * | 2018-07-06 | 2020-01-14 | 江苏恒瑞医药股份有限公司 | 一种新的咪唑啉类衍生物的制备方法 |
WO2020083187A1 (zh) * | 2018-10-22 | 2020-04-30 | 江苏恒瑞医药股份有限公司 | 一种ar拮抗剂联合parp抑制剂在制备治疗***癌的药物中的用途 |
CN113929628A (zh) * | 2020-06-29 | 2022-01-14 | 江苏恒瑞医药股份有限公司 | 一种咪唑啉衍生物的制备方法 |
US11427548B2 (en) | 2015-01-20 | 2022-08-30 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2894151T1 (sl) * | 2012-09-04 | 2021-01-29 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Imidazolinski derivati, postopki za njihovo pripravo in njihove uporabe v medicini |
US20170037004A1 (en) * | 2015-07-13 | 2017-02-09 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
US9963433B2 (en) * | 2016-01-29 | 2018-05-08 | Wayne State University | Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor |
EP3481394A1 (en) * | 2016-07-08 | 2019-05-15 | Janssen Pharmaceutica N.V. | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
CA3113233A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
TWI820276B (zh) * | 2018-12-19 | 2023-11-01 | 美商西建公司 | 經取代之3-((3-胺基苯基)胺基)哌啶-2,6-二酮化合物、其組合物及使用彼等之治療方法 |
EP3897635A4 (en) * | 2018-12-19 | 2022-08-31 | Celgene Corporation | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREOF |
GB201908511D0 (en) | 2019-06-13 | 2019-07-31 | Adorx Therapeutics Ltd | Hydroxamate compounds |
CN113024513A (zh) * | 2021-03-22 | 2021-06-25 | 中国药科大学 | 新型雄激素受体降解剂、制备方法和医药用途 |
CN115850186B (zh) * | 2023-02-07 | 2024-04-09 | 长沙泽达医药科技有限公司 | 一种乙撑硫脲衍生物的晶型及用途 |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030153752A1 (en) | 1998-09-18 | 2003-08-14 | Hirst Gavin C. | Pyrrolopyrimidines as therapeutic agents |
EP1466898A1 (en) | 2001-12-27 | 2004-10-13 | Daiichi Pharmaceutical Co., Ltd. | Beta-amyloid protein production/secretion inhibitors |
US20070010542A1 (en) | 2005-04-15 | 2007-01-11 | Eisai Co., Ltd. | Benzimidazole compound |
CN101048381A (zh) * | 2004-09-09 | 2007-10-03 | 中外制药株式会社 | 新型四氢咪唑衍生物及其用途 |
WO2008001931A2 (en) | 2006-06-27 | 2008-01-03 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
WO2010092371A1 (en) | 2009-02-10 | 2010-08-19 | Astrazeneca Ab | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
CN101817787A (zh) * | 2009-02-26 | 2010-09-01 | 童友之 | 抗***癌的雄性激素受体拮抗剂 |
WO2010118354A1 (en) * | 2009-04-09 | 2010-10-14 | Medivation Prostate Therapeutics, Inc. | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof |
WO2011008543A2 (en) | 2009-06-29 | 2011-01-20 | University Of Delaware | Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
US20110071196A1 (en) | 2009-09-22 | 2011-03-24 | Boehringer Ingelheim International Gmbh | Compounds Which Selectively Modulate The CB2 Receptor |
WO2011103196A1 (en) | 2010-02-17 | 2011-08-25 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
WO2012011840A1 (ru) | 2010-07-22 | 2012-01-26 | Алла Хем, Ллс | Циклические ν,ν'-диарилтиомочевины и ν,ν'-диарилмочевины - антагонисты андрогеновых рецепторов, противораковое средство, способ получения и применения |
WO2012015723A1 (en) | 2010-07-26 | 2012-02-02 | Bristol-Myers Squibb Company | Sulfonamide compounds useful as cyp17 inhibitors |
WO2012050868A1 (en) * | 2010-09-28 | 2012-04-19 | Georgia Tech Research Corporation | Histone deacetylase (hdac) inhibitors targeting prostate tumors and methods of making and using thereof |
US20120110702A1 (en) | 2010-11-03 | 2012-05-03 | Yap Maurice C H | Pesticidal Compositions and Processes Related Thereto |
WO2012119559A1 (en) * | 2011-03-10 | 2012-09-13 | Suzhou Kintor Pharmaceuticals,Inc. | Androgen receptor antagonists and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
EP1546111A2 (fr) * | 2002-10-04 | 2005-06-29 | Laboratoires Fournier S.A. | Composes derives de la 2-thiohydantoine et leur utilisation pour le traitement du diabete |
MX346924B (es) * | 2005-05-13 | 2017-04-05 | Univ California | Compuestos de diarilhidantoina. |
US7709517B2 (en) * | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
SI2894151T1 (sl) * | 2012-09-04 | 2021-01-29 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Imidazolinski derivati, postopki za njihovo pripravo in njihove uporabe v medicini |
-
2013
- 2013-08-26 SI SI201331826T patent/SI2894151T1/sl unknown
- 2013-08-26 CN CN201380004069.5A patent/CN103958480B/zh active Active
- 2013-08-26 DK DK13835193.7T patent/DK2894151T3/da active
- 2013-08-26 BR BR112015004637-1A patent/BR112015004637B1/pt active IP Right Grant
- 2013-08-26 MX MX2015002602A patent/MX368844B/es active IP Right Grant
- 2013-08-26 ES ES13835193T patent/ES2835248T3/es active Active
- 2013-08-26 WO PCT/CN2013/082273 patent/WO2014036897A1/zh active Application Filing
- 2013-08-26 RS RS20201565A patent/RS61242B1/sr unknown
- 2013-08-26 RU RU2015110122A patent/RU2639145C2/ru active
- 2013-08-26 JP JP2015528857A patent/JP6262733B2/ja active Active
- 2013-08-26 PT PT138351937T patent/PT2894151T/pt unknown
- 2013-08-26 KR KR1020157007651A patent/KR102189940B1/ko active IP Right Grant
- 2013-08-26 AU AU2013312587A patent/AU2013312587B2/en active Active
- 2013-08-26 LT LTEP13835193.7T patent/LT2894151T/lt unknown
- 2013-08-26 HU HUE13835193A patent/HUE052904T2/hu unknown
- 2013-08-26 US US14/425,207 patent/US9586947B2/en active Active
- 2013-08-26 CA CA2883545A patent/CA2883545C/en active Active
- 2013-08-26 EP EP13835193.7A patent/EP2894151B1/en active Active
- 2013-08-30 TW TW102131223A patent/TWI617546B/zh active
-
2014
- 2014-11-27 HK HK14111978.7A patent/HK1198476A1/zh unknown
-
2017
- 2017-01-20 US US15/411,517 patent/US9895355B2/en active Active
-
2020
- 2020-12-18 CY CY20201101202T patent/CY1123649T1/el unknown
- 2020-12-21 HR HRP20202050TT patent/HRP20202050T1/hr unknown
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030153752A1 (en) | 1998-09-18 | 2003-08-14 | Hirst Gavin C. | Pyrrolopyrimidines as therapeutic agents |
EP1466898A1 (en) | 2001-12-27 | 2004-10-13 | Daiichi Pharmaceutical Co., Ltd. | Beta-amyloid protein production/secretion inhibitors |
CN101048381A (zh) * | 2004-09-09 | 2007-10-03 | 中外制药株式会社 | 新型四氢咪唑衍生物及其用途 |
US20070010542A1 (en) | 2005-04-15 | 2007-01-11 | Eisai Co., Ltd. | Benzimidazole compound |
WO2008001931A2 (en) | 2006-06-27 | 2008-01-03 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
WO2010092371A1 (en) | 2009-02-10 | 2010-08-19 | Astrazeneca Ab | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
CN101817787A (zh) * | 2009-02-26 | 2010-09-01 | 童友之 | 抗***癌的雄性激素受体拮抗剂 |
WO2010118354A1 (en) * | 2009-04-09 | 2010-10-14 | Medivation Prostate Therapeutics, Inc. | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof |
WO2011008543A2 (en) | 2009-06-29 | 2011-01-20 | University Of Delaware | Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
US20110071196A1 (en) | 2009-09-22 | 2011-03-24 | Boehringer Ingelheim International Gmbh | Compounds Which Selectively Modulate The CB2 Receptor |
WO2011103196A1 (en) | 2010-02-17 | 2011-08-25 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
WO2012011840A1 (ru) | 2010-07-22 | 2012-01-26 | Алла Хем, Ллс | Циклические ν,ν'-диарилтиомочевины и ν,ν'-диарилмочевины - антагонисты андрогеновых рецепторов, противораковое средство, способ получения и применения |
WO2012015723A1 (en) | 2010-07-26 | 2012-02-02 | Bristol-Myers Squibb Company | Sulfonamide compounds useful as cyp17 inhibitors |
WO2012050868A1 (en) * | 2010-09-28 | 2012-04-19 | Georgia Tech Research Corporation | Histone deacetylase (hdac) inhibitors targeting prostate tumors and methods of making and using thereof |
US20120110702A1 (en) | 2010-11-03 | 2012-05-03 | Yap Maurice C H | Pesticidal Compositions and Processes Related Thereto |
WO2012119559A1 (en) * | 2011-03-10 | 2012-09-13 | Suzhou Kintor Pharmaceuticals,Inc. | Androgen receptor antagonists and uses thereof |
Non-Patent Citations (4)
Title |
---|
BIOORGANIC & MEDICIANL CHEMISTRY, vol. 14, no. 7, 2006, pages 2375 - 2385 |
BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 6, 2009, pages 1797 - 1801 |
JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 12, 2011, pages 4092 - 4108 |
ORGANIC LETTERS, vol. 10, no. 15, 2008, pages 3259 - 3262 |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11352351B2 (en) | 2015-01-20 | 2022-06-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
US20160214972A1 (en) * | 2015-01-20 | 2016-07-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
JP2018502925A (ja) * | 2015-01-20 | 2018-02-01 | アルビナス インコーポレイテッド | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
US11427548B2 (en) | 2015-01-20 | 2022-08-30 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
JP2018526364A (ja) * | 2015-09-10 | 2018-09-13 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | アンドロゲン受容体阻害剤の結晶型及びその製造方法 |
CN107001284A (zh) * | 2015-09-10 | 2017-08-01 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的结晶形式及其制备方法 |
CN106518773A (zh) * | 2015-09-10 | 2017-03-22 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的结晶形式及其制备方法 |
US10150739B2 (en) | 2015-09-10 | 2018-12-11 | Jiangsu Hengrui Medicine Co., Ltd. | Crystalline form of androgen receptor inhibitor and preparation method thereof |
WO2017041622A1 (zh) * | 2015-09-10 | 2017-03-16 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的结晶形式及其制备方法 |
TWI708764B (zh) * | 2015-09-10 | 2020-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種雄性激素受體抑制劑的結晶形式及其製備方法 |
AU2016318700B2 (en) * | 2015-09-10 | 2020-05-07 | Jiangsu Hengrui Medicine Co., Ltd. | Crystalline form of androgen receptor inhibitor and preparation method thereof |
CN107001284B (zh) * | 2015-09-10 | 2019-11-22 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的结晶形式及其制备方法 |
US10981926B2 (en) | 2016-01-11 | 2021-04-20 | Janssen Pharmaceutica Nv | Substituted thiohydantoin derivatives as androgen receptor antagonists |
US10000502B2 (en) | 2016-01-11 | 2018-06-19 | Janssen Pharmaceutica Nv | Substituted thiohydantoin derivatives as androgen receptor antagonists |
US10501469B2 (en) | 2016-01-11 | 2019-12-10 | Janssen Pharmaceutica Nv | Substituted thiohydantoin derivatives as androgen receptor antagonists |
CN107530325B (zh) * | 2016-02-19 | 2021-02-23 | 江苏恒瑞医药股份有限公司 | 一种含有咪唑啉类衍生物的药物组合物 |
WO2017140253A1 (zh) | 2016-02-19 | 2017-08-24 | 江苏恒瑞医药股份有限公司 | 一种含有咪唑啉类衍生物的药物组合物 |
US10588978B2 (en) | 2016-02-19 | 2020-03-17 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition containing imidazoline derivative |
RU2749135C2 (ru) * | 2016-02-19 | 2021-06-04 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Фармацевтическая композиция, включающая производное имидазолина |
CN107530325A (zh) * | 2016-02-19 | 2018-01-02 | 江苏恒瑞医药股份有限公司 | 一种含有咪唑啉类衍生物的药物组合物 |
CN110023297A (zh) * | 2016-07-08 | 2019-07-16 | 詹森药业有限公司 | 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物 |
WO2017067530A2 (zh) | 2017-02-13 | 2017-04-27 | 康朴生物医药技术(上海)有限公司 | 一种治疗***癌的组合、药物组合物及治疗方法 |
CN112174895A (zh) * | 2017-12-13 | 2021-01-05 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的晶型及其制备方法 |
CN112300076A (zh) * | 2017-12-13 | 2021-02-02 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的晶型及其制备方法 |
CN112300076B (zh) * | 2017-12-13 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的晶型及其制备方法 |
CN109912509B (zh) * | 2017-12-13 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的晶型及其制备方法 |
CN109912509A (zh) * | 2017-12-13 | 2019-06-21 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的晶型及其制备方法 |
CN112174895B (zh) * | 2017-12-13 | 2022-06-21 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的晶型及其制备方法 |
CN110684046A (zh) * | 2018-07-06 | 2020-01-14 | 江苏恒瑞医药股份有限公司 | 一种新的咪唑啉类衍生物的制备方法 |
CN110684046B (zh) * | 2018-07-06 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 一种新的咪唑啉类衍生物的制备方法 |
CN108976171B (zh) * | 2018-08-27 | 2020-06-16 | 长沙泽达医药科技有限公司 | 化合物、组合物及其在药物制备中的用途 |
CN108976171A (zh) * | 2018-08-27 | 2018-12-11 | 长沙泽达医药科技有限公司 | 化合物、组合物及其在药物制备中的用途 |
CN112584836A (zh) * | 2018-10-22 | 2021-03-30 | 江苏恒瑞医药股份有限公司 | 一种ar拮抗剂联合parp抑制剂在制备治疗***癌的药物中的用途 |
WO2020083187A1 (zh) * | 2018-10-22 | 2020-04-30 | 江苏恒瑞医药股份有限公司 | 一种ar拮抗剂联合parp抑制剂在制备治疗***癌的药物中的用途 |
CN113929628A (zh) * | 2020-06-29 | 2022-01-14 | 江苏恒瑞医药股份有限公司 | 一种咪唑啉衍生物的制备方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014036897A1 (zh) | 咪唑啉类衍生物、其制备方法及其在医药上的应用 | |
JP6309519B2 (ja) | N置換ベンズアミド及びその使用方法 | |
TWI762544B (zh) | 新穎cyp11a1抑制劑 | |
BR112020000823A2 (pt) | composto, medicamento, métodos para ativar um receptor de orexina tipo 2 e para profilaxia ou tratamento de narcolepsia, e, uso de um composto ou sal. | |
EP3937943A1 (en) | Novel small molecule inhibitors of tead transcription factors | |
AU2020215380A2 (en) | Heterocyclic compound and use thereof | |
JP2010518026A (ja) | ナトリウムチャネルが介在する疾患または状態の治療に有用なピリドピリミジノン化合物 | |
CA2942871A1 (en) | Ror-gamma modulators and uses thereof | |
CA2770932C (en) | Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines | |
WO2013104257A1 (zh) | 多环类衍生物、其制备方法及其在医药上的应用 | |
WO2014183555A1 (zh) | 环烷基甲酸类衍生物、其制备方法及其在医药上的应用 | |
EP2976341A1 (en) | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | |
JP2017521466A (ja) | アルドステロン合成酵素阻害薬 | |
KR20160142887A (ko) | 폴리시클릭 hERG 활성화제 | |
CA3191456A1 (en) | Novel compounds having inhibitory activity on prostaglandin e2 receptor and uses thereof | |
CN117776987A (zh) | 苯并[7]环烯类衍生物、包含其的药物组合物及其医药用途 | |
WO2019087163A1 (en) | Polycyclic herg activators | |
WO2019087162A1 (en) | Polycyclic herg activators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201380004069.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13835193 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015528857 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/002602 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2883545 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14425207 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2013312587 Country of ref document: AU Date of ref document: 20130826 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20157007651 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2015110122 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015004637 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015004637 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150302 |